Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial (2021)

First Author: Heaney L

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(20)30397-0

Publication URI: http://dx.doi.org/10.1016/s2213-2600(20)30397-0

Type: Journal Article/Review

Parent Publication: The Lancet Respiratory Medicine

Issue: 1